Fibrates protect against vascular endothelial dysfunction induced by paclitaxel and carboplatin chemotherapy for cancer patients: a pilot study
Authors:
- 26 December 2014
- journal article
- research article
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 20 (4) , 829-838
Abstract
Although we previously demonstrated that paclitaxel and carboplatin chemotherapy (TCchem) is associated with vascular toxicities, the underlying mechanisms remain unclear. Cisplatin is known to inhibit PPARα following microvascular damage to the kidneys. The primary aim of this study was to evaluate whether TCchem induces vascular endothelial dysfunction via systemic PPARα deficiency. In addition, human umbilical vein endothelial cells (HUVECs) were used to elucidate the mechanisms responsible for TCchem-induced vascular toxicities. This study enrolled 45 gynecological cancer patients with normal lipid profiles who underwent surgical treatment followed by TCchem. The elevated triglyceride (TG) group included patients (n = 19) who exhibited hypertriglyceridemia during TCchem, and the stable TG group (n = 15) included patients with a normal TG level. Eleven patients exhibiting hypertriglyceridemia during TCchem were administered bezafibrate (fibrate group). Endothelial dysfunction was evaluated based on flow-mediated dilation (FMD) values and serum pentraxin-3 levels measured before TCchem and immediately after the final TCchem. HUVECs were used to elucidate the biological mechanisms underlying the endothelial dysfunction induced by TCchem. The administration of TCchem induced hypertriglyceridemia in 66 percent of the participants, and bezafibrate reduced the serum TG levels. Meanwhile, the decrease in flow-mediated dilatation (%FMD) induced by TCchem improved following treatment with bezafibrate. The serum pentraxin-3 level increased rapidly after TCchem and decreased following bezafibrate treatment. An in vitro examination demonstrated TCchem attenuated nitric oxide production and PPARα activity in HUVECs, which was partially improved by treatment with bezafibrate. Bezafibrate prevents endothelial dysfunction induced by TCchem via TG-dependent and TG-independent mechanisms.Keywords
This publication has 43 references indexed in Scilit:
- Impact of platinum-based chemotherapy on the progression of atherosclerosisClimacteric, 2011
- Cardiovascular Risk Factors and Morbidity in Long-Term Survivors of Testicular Cancer: A 20-Year Follow-Up StudyJournal of Clinical Oncology, 2010
- Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammationJournal of Lipid Research, 2009
- Serum C-Reactive Protein as Independent Prognostic Variable in Patients with Ovarian CancerClinical Cancer Research, 2008
- Metabolomics as an Extension of Proteomic Analysis: Study of Acute Kidney InjurySeminars in Nephrology, 2007
- Statins Activate Peroxisome Proliferator-Activated Receptor γ Through Extracellular Signal-Regulated Kinase 1/2 and p38 Mitogen-Activated Protein Kinase–Dependent Cyclooxygenase-2 Expression in MacrophagesCirculation Research, 2007
- Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancerEuropean Journal of Cancer, 2004
- Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune responseNature, 2002
- Statin-induced inhibition of the Rho-signaling pathway activates PPARα and induces HDL apoA-IJournal of Clinical Investigation, 2001
- The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A proteinImmunology Today, 1994